BioNotebook: PhaseBio closes $40m Series C round led by AstraZeneca, plus five other VC financings
This article was originally published in Scrip
AstraZeneca led a $40m Series C venture capital round that will fund PhaseBio's Phase IIa clinical trials for drug candidates to treat diabetes and heart failure – two key areas of interest for the UK-based big pharma company.
You may also be interested in...
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.
Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.